100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 StudiesNoah Rosen, Abraham J. Nagy, Eric Pearlman et al.|Headache The Journal of Head and Face Pain|2018Cited by 35